Skip to content

Funding Announcements

Filter

Filter & sort

Keyword

Tag

Round

Sort by

Clear

The latest funding rounds from the UK tech ecosystem. Updated 4 November 2026.

Announcements

6,261

Total raised

£165B

disclosed amounts

This month

£10.5M

raised so far

Series A
£3.0M

Guinness Asset Management led the Series A round to support product development and team expansion.

"We are delighted to welcome Guinness to the Neighbourly team and for Ashley to join us on the board. He immediately understood the Neighbourly proposition and the value it delivers for businesses and local good causes alike, against the backdrop of the rapidly evolving ESG landscape. Our strong belief is that businesses must prioritise the proven power of local good causes, who are the backbone of our communities. A thriving community and resilient population of hyper-local causes is vital to the success of both society and the economy."
— Steve Butterworth, CEO
Seed
£200K

Origin Capital has led a seed investment in CyTAL to support the growth of its ProtoCrawler software.

"“We’re delighted to receive an investment from Origin, and the process we have been through to get here has really helped us to validate our future plans and ambitions. We’ve listened carefully to what our customers and the market are telling us, and developed ProtoCrawler accordingly. We look forward to welcoming Origin onto the board and exploiting their insights to help us become a leading player in cyber security product assurance and testing software.”"
— Matt Freeman, CEO
Series C
£35.9M

The London software business has closed a Series C round backed by Insight Partners and existing shareholders to fund international growth.

"At Insight Partners, we invest in fast-scaling software companies. The Pollinate platform creates white-labelled digital marketplaces for the business customers of the world’s largest banks"
— Emmet Keeffe III, Operating Partner at Insight Partners and Founder of Insight IGNITE
Seed
£2.0M

The seed round was led by XTX Ventures and Prostate Cancer Research to support regulatory approvals and clinical studies.

"We are tremendously excited about the potential of this system to enhance our ability to detect cancer accurately and early. We are now looking forward to working with hospitals and radiology and urology partners to prove the technology and bring it into clinical use. Covid-19 has created a serious backlog in cancer screening and Lucida Medical is well placed to help us clear this and improve the care that we offer further over the coming years."
— Evis Sala, Chief Medical Officer